Mosquitoes Are a Choice
6 hours ago
- Mosquito-borne diseases like dengue and malaria are resurging in the US due to rising temperatures and pesticide resistance, with nearly 4,000 dengue cases in 2024.
- Genetic engineering (Oxitec) inserts a lethal gene into male mosquitoes that kills female offspring, reducing populations by up to 95% in trials, but faced 15 years of regulatory limbo across USDA, FDA, and EPA.
- Wolbachia-infected mosquitoes offer an alternative: the bacterium reduces virus transmission and causes sterile mating, with trials achieving 85% population reduction and 70% fewer dengue cases; MosquitoMate received full commercial registration in 2024.
- US biotech regulation (1986 Coordinated Framework) is outdated, leading to delays and jurisdictional confusion; reforms like expedited review vouchers exist but are insufficient.
- Increasing regulatory agency capacity and adopting fee-based systems (like FDA’s drug review) could speed approvals and help eliminate mosquito-borne diseases domestically.